Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.

Moayedi B, Gharagozloo M, Esmaeil N, Maracy MR, Hoorfar H, Jalaeikar M.

Eur J Haematol. 2013 Mar;90(3):202-9. doi: 10.1111/ejh.12061. Epub 2013 Jan 20.

PMID:
23278124
2.

Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.

Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z.

Fundam Clin Pharmacol. 2009 Jun;23(3):359-65. doi: 10.1111/j.1472-8206.2009.00681.x. Epub 2009 May 7.

PMID:
19453758
3.

Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E.

Haematologica. 2007 May;92(5):583-8.

4.
5.

Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.

Hagag AA, Hamam MA, Taha OA, Hazaa SM.

Infect Disord Drug Targets. 2015;15(2):98-105.

PMID:
26205801
6.

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.

Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.

Circulation. 2007 Apr 10;115(14):1876-84. Epub 2007 Mar 19.

7.

Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.

Hagag AA, Elfaragy MS, Elrifaey SM, Abd El-Lateef AE.

Infect Disord Drug Targets. 2015;15(3):189-95.

PMID:
26239735
8.

A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.

Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.

Hemoglobin. 2006;30(2):263-74.

PMID:
16798652
9.

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.

Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.

Br J Haematol. 2010 Feb;148(3):466-75. doi: 10.1111/j.1365-2141.2009.07970.x. Epub 2009 Nov 12.

PMID:
19912219
10.

Combined therapy with deferiprone and desferrioxamine in thalassemia major.

Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessì C, Leoni G, Muroni PP, Galanello R.

Haematologica. 2005 Oct;90(10):1309-14.

11.

Combined therapy with deferiprone and desferrioxamine.

Wonke B, Wright C, Hoffbrand AV.

Br J Haematol. 1998 Nov;103(2):361-4.

PMID:
9827905
12.

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD.

Blood. 2012 Aug 2;120(5):970-7. doi: 10.1182/blood-2012-02-412692. Epub 2012 May 15.

13.

Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.

Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.

Eur J Haematol. 2010 Jan 1;84(1):72-8. doi: 10.1111/j.1600-0609.2009.01342.x.

PMID:
19732137
14.
15.
16.

Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.

Farmaki K, Tzoumari I, Pappa C.

Blood Cells Mol Dis. 2011 Jun 15;47(1):33-40. doi: 10.1016/j.bcmd.2011.03.007. Epub 2011 Apr 29.

PMID:
21531154
17.
18.

Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients.

Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A.

Br J Haematol. 2003 Apr;121(1):187-9.

PMID:
12670352
19.

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S.

Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004450. Review. Update in: Cochrane Database Syst Rev. 2013;8:CD004450.

PMID:
16235363
20.

Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.

Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.

Haematologica. 2003 Dec;88(12):1423-5. No abstract available.

Supplemental Content

Support Center